168 related articles for article (PubMed ID: 8645080)
21. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
22. Synchronous occurrence of anaplastic, follicular and papillary carcinomas with follicular adenoma in thyroid gland.
Bhargav PR; Gayathri KB
Indian J Pathol Microbiol; 2011; 54(2):414-5; author reply 415. PubMed ID: 21623114
[No Abstract] [Full Text] [Related]
23. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
24. miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer.
Xiong Y; Kotian S; Zeiger MA; Zhang L; Kebebew E
PLoS One; 2015; 10(8):e0130496. PubMed ID: 26244545
[TBL] [Abstract][Full Text] [Related]
25. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation signatures identify biologically distinct thyroid cancer subtypes.
Rodríguez-Rodero S; Fernández AF; Fernández-Morera JL; Castro-Santos P; Bayon GF; Ferrero C; Urdinguio RG; Gonzalez-Marquez R; Suarez C; Fernández-Vega I; Fresno Forcelledo MF; Martínez-Camblor P; Mancikova V; Castelblanco E; Perez M; Marrón PI; Mendiola M; Hardisson D; Santisteban P; Riesco-Eizaguirre G; Matías-Guiu X; Carnero A; Robledo M; Delgado-Álvarez E; Menéndez-Torre E; Fraga MF
J Clin Endocrinol Metab; 2013 Jul; 98(7):2811-21. PubMed ID: 23666970
[TBL] [Abstract][Full Text] [Related]
27. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
28. Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma.
Kim TH; Lee M; Kwon AY; Choe JH; Kim JH; Kim JS; Hahn SY; Shin JH; Chung MK; Son YI; Ki CS; Yim HS; Kim YL; Chung JH; Kim SW; Oh YL
Histopathology; 2018 Mar; 72(4):648-661. PubMed ID: 28940583
[TBL] [Abstract][Full Text] [Related]
29. Blood group antigen expression in malignant tumors of the thyroid: a parallel between medullary and nonmedullary carcinomas.
Larena A; Vierbuchen M; Fischer R
Langenbecks Arch Chir; 1995; 380(5):269-72. PubMed ID: 7500798
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
BMC Cancer; 2006 Nov; 6():260. PubMed ID: 17076909
[TBL] [Abstract][Full Text] [Related]
31. Familial nonmedullary thyroid carcinoma.
Malchoff CD; Malchoff DM
Cancer Control; 2006 Apr; 13(2):106-10. PubMed ID: 16735984
[TBL] [Abstract][Full Text] [Related]
32. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment.
Grossman RF; Tu SH; Duh QY; Siperstein AE; Novosolov F; Clark OH
Arch Surg; 1995 Aug; 130(8):892-7; discussion 898-9. PubMed ID: 7632152
[TBL] [Abstract][Full Text] [Related]
33. [Familial nommedullary thyroid cancer].
Santos RB; Melo TG; Assumpção LV
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):769-73. PubMed ID: 17891240
[TBL] [Abstract][Full Text] [Related]
34. [Correlations between cytology and histology in thyroid pathology. Case 2. Possible malignant lesion (insular carcinoma/poorly differentiated follicular carcinoma)].
Cochand-Priollet B
Ann Pathol; 2009 Apr; 29(2):91-4. PubMed ID: 19364580
[No Abstract] [Full Text] [Related]
35. Gene Fusions in Thyroid Cancer.
Yakushina VD; Lerner LV; Lavrov AV
Thyroid; 2018 Feb; 28(2):158-167. PubMed ID: 29281951
[TBL] [Abstract][Full Text] [Related]
36. Thyroid tumors with follicular architecture.
Turk AT; Wenig BM
Ann Diagn Pathol; 2019 Feb; 38():51-58. PubMed ID: 30419427
[TBL] [Abstract][Full Text] [Related]
37. [Histological variants (subtypes) of differentiated thyroid carcinoma].
Abduluakhab M; Mikhaĭlov I; Gavrilov M
Khirurgiia (Sofiia); 1997; 50(3):31-4. PubMed ID: 9739840
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical study of glypican 3 in thyroid cancer.
Yamanaka K; Ito Y; Okuyama N; Noda K; Matsumoto H; Yoshida H; Miyauchi A; Capurro M; Filmus J; Miyoshi E
Oncology; 2007; 73(5-6):389-94. PubMed ID: 18511877
[TBL] [Abstract][Full Text] [Related]
39. Family with nonmedullary thyroid neoplasms.
Kobayashi K; Tanaka Y; Ishiguro S; Mori T; Mitani Y; Shigemasa C
J Surg Oncol; 1995 Apr; 58(4):274-7. PubMed ID: 7723373
[TBL] [Abstract][Full Text] [Related]
40. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
